miR125a inhibits the migration and invasion of liver cancer cells via suppression of the PI3K/AKT/mTOR signaling pathway

Author：

Publisher： Spandidos Publications

E-ISSN： 1792-1082|10|2|681-686

ISSN： 1792-1074

Source： Oncology Letters, Vol.10, Iss.2, 2015-01, pp. : 681-686

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

In order to explore the regulation of the invasive ability of hepatocellular carcinoma cells and the underlying mechanism, mimics sequences of microRNA (miR)125a (miR125a3p/5p) and scramble sequences (miR125a3ps/5ps) were transfected into human hepatocellular carcinoma cell lines, HCCLM3 and HepG2, and the nonmalignant epithelioid hepatic cell line QZG. To inhibit and upregulate the expression of miR125a individually. Protein expression was detected by western blotting, and the cell proliferation and migration abilities were evaluated by soft agar colony formation and Transwell assay, respectively. It was revealed that the expression of miR125a was downregulated in HepG2 and HCCLM3 cells compared with that of QZG cells, and expression was markedly lower in HCCLM3 cells than that in HepG2 cells (P<0.01). The colony formation and migration rates of the cells transfected with miR125a3p/5p were decreased compared with negative controls, but were increased in cells transfected with miR125a3p3/5ps (P<0.01). The protein and messenger RNA expression of phosphoinositide 3kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) was decreased following transfection with miR125a5p, whereas expression was increased compared with negative controls following transfection with miR125a5ps (P<0.01). Furthermore, the proliferation and migration abilities of cells were attenuated following inhibition of the PI3K/AKT/mTOR pathway by LY294002. The results of the present study indicated that miR125a inhibits the invasive ability of hepatocellular carcinoma cells via regulation of the PI3K/AKT/mTOR pathway.